SYSTEMIC LUPUS ERYTHEMATOSUS

This study tests whether teprenone, a stomach-protecting drug, can reduce gastrointestinal damage caused by high-dose steroids in people with lupus. One hundred participants will be randomly assigned to take either teprenone or the standard acid-blocker omeprazole for 12 weeks. T…

This early-stage trial tests a new drug called HN2302, a type of CAR-T cell therapy made inside the body, for people with autoimmune diseases like lupus and scleroderma. The study will enroll 12 adults to check safety and see if it works. Researchers will monitor side effects and…

This phase 2 trial tests a single infusion of FT819, a CAR T-cell therapy made from donor cells, in 53 people with moderate-to-severe lupus nephritis that hasn't responded to other treatments. The goal is to see if it can improve kidney function and reduce disease activity. Parti…

This early-phase study tests a new drug called WGb-0301 for people with autoimmune diseases (like lupus or autoimmune hepatitis) that haven't responded to standard treatments. The drug uses mRNA technology to target and clear certain immune cells (B cells) that are causing the di…

This early-stage trial tests a new drug called HBM7020 in 63 people. It starts with healthy volunteers to check safety, then moves to patients with autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see if the drug is safe and…

This study tests a new treatment using CD19 CAR T cells for people with severe autoimmune diseases that haven't improved with standard therapies. The treatment involves collecting a patient's own immune cells, modifying them to target and destroy certain immune cells, and infusin…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase study tests a new mRNA drug that targets two proteins (CD19 and BCMA) on immune cells. The goal is to clear the faulty B cells and plasma cells that attack the body in autoimmune diseases. 27 adults aged 18-70 with relapsed or hard-to-treat autoimmune diseases wi…

This early study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses donor immune cells engineered to target and destroy the faulty immune cells driving the disease. Fourteen adults will receive a single inf…

This study compares two drugs, telitacicept and belimumab, for controlling systemic lupus erythematosus (SLE) in adults aged 18-65. Participants choose their treatment with their doctor, and researchers track how well each drug reduces lupus activity and kidney problems. The goal…

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This early-phase study tests a new drug called budoprutug in 30 adults with active lupus who haven't responded well to standard treatments. The drug targets and depletes certain immune cells (B cells) to help control the disease. The main goals are to check safety and how the bod…

This study tests whether a diet tailored to a person's genetic makeup can help control lupus and improve quality of life. Researchers will screen 100 adults with lupus for specific genes (HLA DQ2 and DQ8) and then assign those who have them to either a personalized diet plan or n…

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This study tests a new medicine called TQH3906 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial will involve 198 participants and aims to see if the drug can reduce lupus symptoms better than a placebo. It is a Phase 2 study, meaning it …

This study tests a drug called anifrolumab in children aged 5 to 18 with moderate to severe lupus. The goal is to see how the drug moves through the body and if it is safe. Participants will continue their usual lupus treatments while receiving the study drug. The trial involves …

This early-stage study tests an experimental treatment called P-CD19CD20-ALLO1 in 162 adults with severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the immune system. The main goals are …

This pilot study will test whether virtual Reiki therapy can help reduce pain and improve well-being in people with lupus. Twenty adults with lupus will receive weekly 20-minute Reiki sessions over video for 8 weeks, while continuing their usual care. Researchers will measure cha…

This study looks at whether a 12-week aerobic exercise program can improve thinking skills and reduce disease activity in people with lupus. Researchers will test memory, attention, and walking ability before and after the program. The goal is to see if exercise can ease lupus-re…

This study will collect health data and samples from 100 adults with rheumatoid diseases when they change treatments. Researchers will use artificial intelligence to find patterns that could predict when a treatment change is needed. The goal is to improve personalized care and u…

This study looks at how the lupus medication Saphnelo (anifrolumab) is being used in women aged 15 to 50 who could become pregnant. Researchers will track how many women take the drug and describe their health details. The goal is to gather real-world safety information required …

This study is creating a large collection of medical data and blood samples from 450 adults with autoimmune diseases (rheumatoid arthritis, lupus, or scleroderma) and 50 healthy volunteers. Researchers will use advanced lab techniques to find unique biological markers that could …

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …